Top Strong Buy Stocks for October 31: PMT, NWG, and Others
Zacks Rank #1 Stocks: Five stocks have been added to the Zacks Rank #1 (Strong Buy) List, including PennyMac Mortgage Investment Trust, NatWest Group, Phibro Animal Health, Centene, and ACNB, all of which have seen positive earnings estimate revisions over the past 60 days.
Earnings Growth: Each of the highlighted companies has experienced an increase in the Zacks Consensus Estimate for their current year earnings, with PennyMac leading at 10.3% growth.
Investment Opportunities: The article suggests that these stocks are under the radar of Wall Street, presenting a unique opportunity for investors to potentially capitalize on significant growth, with previous recommendations yielding returns of +171%, +209%, and +232%.
Expert Recommendations: Zacks Investment Research offers a free report on the "7 Best Stocks for the Next 30 Days," encouraging investors to consider these handpicked stocks for potential high returns.
Trade with 70% Backtested Accuracy
Analyst Views on PAHC
About PAHC
About the author

Phibro Animal Health to Announce Q2 Financial Results on February 4, 2026
- Earnings Announcement: Phibro Animal Health Corporation is set to release its second-quarter financial results on February 4, 2026, after market close, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: Management will host a conference call on February 5, 2026, at 9:00 AM Eastern Time to provide insights into the financial results, aiming to bolster investor confidence in the company's future prospects.
- Participation Information: Interested parties can join the call by dialing +1 (888) 330-2022 for U.S. and Canada or +1 (365) 977-0051 for international callers, ensuring broad dissemination of information.
- Webcast Replay Availability: A replay of the webcast will be available approximately two hours after the live event, allowing investors who could not attend in real-time to access key information, further enhancing engagement between the company and its investors.

Insulet's Omnipod 5 Platform Achieves Over $200 Million in International Revenue
- Market Share Growth: Insulet's Omnipod 5 platform achieved over $200 million in international revenue for the first time in Q3 2025, driven by rapid product adoption and increasing market demand, significantly enhancing the company's competitive position.
- Surge in U.S. Revenue: U.S. Omnipod revenues grew by 25.6% year-over-year, exceeding the high end of the company's guidance, indicating sustained strong demand for Omnipod 5 among both Type 1 and Type 2 diabetes patients, further expanding the company's market share.
- Strong Financial Health: As of Q3 2025, Insulet reported cash and cash equivalents of $757.4 million with current debt of $80 million, showcasing robust financial stability amid economic uncertainty, which supports future expansion and investment.
- Ongoing Strategic Investments: Insulet is increasing investments in platform innovation, including sensor integrations with Dexcom and Abbott, which are expected to further enhance its technological advantage and drive growth in global markets.






